Time to reconsider subcutaneous mastectomy for breast-cancer prevention?

Lancet Oncology

Volumn 6, Issue 6, 2005, Pages 431-434

  Metcalfe, Kelly A ^a,b   Semple, John L ^b   Narod, Steven A ^c  

^a UNIVERSITY OF TORONTO   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER RISK; CLINICAL PRACTICE; ESTHETICS; FEMALE; GENETIC ANALYSIS; HUMAN; MASTECTOMY; MEDICAL RESEARCH; MUTATIONAL ANALYSIS; OVARIECTOMY; PATIENT SATISFACTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION; SUBCUTANEOUS MASTECTOMY; TREATMENT OUTCOME;

EID: 19944402563     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(05)70210-2     Document Type: Note

References (28)

1. IS Fentiman Prophylactic mastectomy: Deliverance or delusion? We don't know, so we need to start registering all cases now BMJ 317 1998 1402-1403
2. FS Collins BRCA1: Lots of mutations, lots of dilemmas N Engl J Med 334 1996 186-188
3. Hartmann LC, Schaid DJ, Woods JE, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. New Engl J Med 1999; 340: 77-85.
4. Zeigler L, Kroll S. Primary breast cancer after prophylactic mastectomy. Am J Clin Oncol 1991; 14: 451-54.
5. Eldar S, Meguid MM, Beatty, JD. Cancer of the breast after subcutaneous mastectomy. Am J Surg 1984; 148: 692-93.
6. Goodnight JE, Quagliana JM, and Morton DL. Failure of subcutaneous mastectomy to prevent the development of breast cancer. J Surg Oncol 1984; 26: 198-201
7. Willemsen H, Kaas R, Rutgers E. Breast carcinoma in residual breast tissue after prophylactic bilateral subcutaneous mastectomy. Eur J Surg Oncol 1998; 24: 331-32.
8. Hartmann LC, Sellers TA, Schaid DJ, et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst 2001; 93: 1633-37.
9. Rebbeck TR, Friebel T, Lynch HT, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: The PROSE Study Group. J Clin Oncol 2004; 22: 1055-62.
10. Meijers-Heijboer M, VanGeel B, VanPutten W, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2001; 345: 158-64.
11. Klijn JGM, Van Geel AN, Meijers-Heijboer H, et al. Long-term follow-up of the Rotterdam study on prophylactic mastectomy versus surveillance in BRCA1/2 mutation carriers. J Clin Oncol 2004; 22: 9502.
12. Lodder LN, Frets PG, Trijsburg RW, et al. One year follow-up of women opting for presymptomatic testing for BRCA1 and BRCA2: Emotional impact of the test outcome and decisions on risk management (surveillance or prophylactic surgery). Breast Cancer Res Treat 2002; 73: 97-112.
13. Lerman C, Hughes C, Croyle RT, et al. Prophylactic surgery decisions and surveillance practices one year following BRCA1/2 testing. Prev Med 2000; 31: 75-80.
14. Botkin JR, Smith KR, Croyle RT, et al. Genetic testing for a BRCA1 mutation: Prophylactic surgery and screening behavior in women 2 years post testing. Am J Med Genet 2003; 118A: 201-09.
15. Metcalfe KA, Liede A, Hoodfar E, et al. An evaluation of needs of female BRCA1 and BRCA2 carriers undergoing genetic counselling. J Med Genet 2000; 37: 866-74.
16. Julian-Reynier CM, Bouchard LJ, Evans DG, et al. Women's attitudes toward preventive strategies for hereditary breast or ovarian carcinoma differ from one country to another: Differences among English, French, and Canadian women. Cancer 2001; 92: 959-68.
17. Spears SL, Carter ME, Schwarz K. Prophylactic mastectomy: Options and reconstructive alternatives. Plast Reconst Surg 2005; 115: 891-909.
18. Temple WJ, Lindsay RL, Magi E, Urbanski SJ. Technical considerations for prophylactic mastectomy in patients at high risk for breast cancer. Am J Surg 1991; 161: 413-15.
19. Baron RH, Borgen PI. Genetic susceptibility for breast cancer: Testing and primary prevention options. Oncol Nurs Forum 1997; 24: 461-68.
20. Morrow M. Identification and management of the woman at increased risk for breast cancer development. Breast Cancer Res Treat 1994; 34: 53-60.
21. Eisen A, Weber BL. Prophylactic mastectomy - the price of fear. N Engl J Med 1999; 340: 137-38.
22. Pennisi VR, Capozzi A. Subcutaneous mastectomy data: A final statistical analysis of 1500 patients. Aesthetic Plast Surg 1989; 13: 15-21.
23. Gerber B, Krause A, Reimer T, et al. Skin-sparing mastectomy with conservation of the nipple-areola complex and autologous reconstruction is an oncologically safe procedure. Ann Surg 2003; 238: 120-27.
24. Al-Ghazal SK, Blamey RW. Subcutaneous mastectomy with implant reconstruction: Cosmetic outcome and patient satisfaction. Eur J Surg Oncol 2000; 26: 137-41.
25. Parkin DM, Whelan SL, Ferlay J, et al. Cancer incidence in five continents, Vol VIII. Lyon: IARC Press, 2004
26. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 1998; 90: 1371-88.
27. Metcalfe KA, Snyder C, Seidel J, et al. The use of tamoxifen and other preventive measures among healthy women who carry a BRCA1 or BRCA2 mutation. Fam Cancer (in press).
28. Cheung KL, Blamey RW, Robertson JF, et al. Subcutaneous mastectomy for primary breast cancer and ductal carcinoma in situ. Eur J Surg Oncol 1997; 23: 343-47.